Julian A Simon, 635300 Hudson St, Seattle, WA 98118

7173063, Feb 6, 2007

Nov 10, 2000

10/129936

John R. Lamb - Shoreline WA, US
Julian Simon - Seattle WA, US
Heather Dunstan - San Diego CA, US
Stephen H. Friend - Bryn Mawr PA, US

Fred Hutchinson Cancer Research Center - Seattle WA

A61K 31/16
A61K 31/165
C07C 241/00
C07C 233/00

514615, 514613, 514614, 514616, 514617, 564123, 564148, 564150, 564153

Methods for the treatment of a proliferative disorder are provided in which a subject in need of such treatment is administered an effective amount of a compound selected from: compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein Xand Xare independently H, Cl, F, Br, I, CN, CFor NO, and Aris a substituted or unsubstituted aryl or a substituted or unsubstituted heteroaryl; and compounds of formula (II) wherein Xand Xare each independently H, Cl, F, Br, I, CN, CFor NO; Y is (C–C)alkylene or (C–C)heteroalkylene; and Z is Cl, F, Br, I, CN, CFor NO.

7241804, Jul 10, 2007

Aug 18, 2000

10/069431

David M. Hockenberry - Seattle WA, US
Julian A. Simon - Seattle WA, US

Fred Hutchinson Cancer Research Center - Seattle WA

A61K 31/35

514450, 549267

The present invention provides agents and compositions for modulating the apoptotic state of a cell. The agents comprise derivatives of antimycins which bind to an anti-apoptotic Bcl-2 family member protein. Further, the agents preferentially induce apoptosis in cells that over-express anti-apoptotic Bcl-2 family member proteins and typically exhibit reduced binding affinity for cytochrome B. Pharmaceutical uses of the agents and compositions include treating apoptosis-associated disease, such as neoplasia and drug resistance, are also disclosed.

7514406, Apr 7, 2009

Nov 26, 2002

10/496031

Antonio Bedalov - Seattle WA, US
Daniel E. Gottschling - Seattle WA, US
Julian Simon - Seattle WA, US

Fred Hutchinson Cancer Research Center - Seattle WA

A61K 38/00
A61K 31/50

514 12, 514247

A method for identifying a compound that inhibits the NAD-dependent deacetylase activity of a SIR2 protein is disclosed. These compounds are useful for the treatment of cancers and other diseases, through the activation of silenced genes, through the promotion of apoptosis in cancerous cells, and through the inhibition of transcriptional repressor activity in oncogenes.

8232314, Jul 31, 2012

Jan 15, 2008

12/014470

Henry C. Ou - Seattle WA, US
Felipe Santos - Seattle WA, US
Edwin W. Rubel - Seattle WA, US
David W. Raible - Seattle WA, US
Julian A. Simon - Seattle WA, US

University of Washington - Seattle WA
Fred Hutchinson Cancer Research Center - Seattle WA

A01N 43/12

514443

The present invention provides methods of identifying compounds that protect against ototoxicity induced by one or more noxious stimuli, and methods of treating an individual with compounds identified using the present screening methods. Also provided are compounds demonstrated to have otoprotective effects.

2005023, Oct 27, 2005

Jan 14, 2005

11/036645

David Hockenbery - Seattle WA, US
Julian Simon - Seattle WA, US

Fred Hutchinson Cancer Research Center - Seattle WA

A61K031/365

514450000, 549267000

Disclosed are 2-methoxy antimycin derivatives or analogs that modulate apoptosis by binding to the hydrophobic groove of a Bcl-2 family member protein (e.g., Bcl-2 or BCl-x). The 2-methoxy antimycin derivatives or analogs are used in disclosed methods for treating apoptosis-associated diseases such as, for example, neoplastic disease (e.g., cancer) or other proliferative diseases associated with the over-expression of a Bcl-2 family member protein.

2006018, Aug 24, 2006

Feb 22, 2006

11/359161

Henry Ou - Seattle WA, US
Felipe Santos - Seattle WA, US
Edwin Rubel - Seattle WA, US
David Raible - Seattle WA, US
Julian Simon - Seattle WA, US

A61K 49/00

424009200, 424009600

The present invention provides methods of identifying compounds that protect against ototoxicity induced by one or more noxious stimuli, and methods of treating an individual with compounds identified using the present screening methods. Also provided are compounds demonstrated to have otoprotective effects.

2009020, Aug 13, 2009

Jun 25, 2007

11/768111

David M. Hockenberry - Seattle WA, US
Julian A. Simon - Seattle WA, US

Fred Hutchison Cancer Research Center - Seattle WA

A61K 31/357
C07D 321/00
C12Q 1/02

514450, 549347, 435 29

The present invention provides agents and compositions for modulating the apoptotic state of a cell. The agents comprise derivatives of antimycins which bind to an anti-apoptotic Bcl-2 family member protein. Further, the agents preferentially induce apoptosis in cells that over-express anti-apoptotic Bcl-2 family member proteins and typically exhibit reduced binding affinity for cytochrome B. Pharmaceutical uses of the agents and compositions include treating apoptosis-associated disease, such as neoplasia and drug resistance, are also disclosed.

2011013, Jun 9, 2011

Dec 8, 2010

12/963396

Kelly N. Owens - Seattle WA, US
Anna L. Corke - Seattle WA, US
Henry C. Ou - Seattle WA, US
Edwin W. Rubel - Seattle WA, US
David W. Raible - Seattle WA, US
Julian A. Simon - Seattle WA, US

University of Washington - Seattle WA
Fred Hutchinson Cancer Research Center - Seattle WA

A61K 33/24
A61K 31/522
A61K 31/122
A61K 31/4965
A61K 31/546
A61K 31/4706
A61K 31/138
A61K 31/438
A61K 31/7036
A61P 17/00
A61P 27/16

424649, 51426334, 514682, 51425506, 514202, 514313, 514651, 514278, 51425216, 514 39

The invention provides compounds, compositions and methods that can be used for the attenuation of damage to sensory hair cells and symptoms thereof. More particularly, the invention identifies drugs that can be used to protect sensory hair cells from ototoxic medications, noise-induced damage and age-related loss.